Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores

Yale Journal of Biology and Medicine

Volumn 89, Issue 1, 2016, Pages 5-21

  Arbor, Sage C ^a   Lafontaine, Mike ^a   Cumbay, Medhane ^a  

^a IN   (United States)

Author keywords

Alzheimer; Amyloid; Amyloid precursor protein; Amyloid beta; APBA; ApoE; A ; Cholesterol; Dementia; Ganglioside; Lipid raft; Mint; Perforin; Plaque; Pore; Presenilin; Secretase; barrel; secretase; strand; secretase

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PRECURSOR PROTEIN BINDING FAMILY A; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-43]; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN LIKE PROTEIN 1; AMYLOID PRECURSOR PROTEIN LIKE PROTEIN 2; APOLIPOPROTEIN E; AZD 3293; BAPINEUZUMAB; BETA SECRETASE 1; BETA SECRETASE 2; CHOLESTEROL; CRENEZUMAB; GAMMA SECRETASE; GANGLIOSIDE; SOLANEZUMAB; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIPID RAFT; MEMBRANE CONDUCTANCE; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; WESTERN BLOTTING; ANIMAL; CHEMISTRY; MEMBRANE MICRODOMAIN; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; HUMANS; MEMBRANE MICRODOMAINS;

EID: 84962023287     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (231)

1. ittner LM, Götz J. Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):65-72.
2. Gotz J, Lim YA, Ke YD, eckert A, ittner LM. Dissecting toxicity of tau and beta-amyloid. Neurodegener Dis. 2010;7(1-3):10-12.
3. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387-403.
4. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325(6106):733-6.
5. Motter R, vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson- Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol. 1995;38(4):643-8.
6. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-34.
7. Clark RF, Hutton M, Fuldner M, Froelich S, Karran E, Talbot C, et al. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer’s Disease Collaborative Group. Nat Genet. 1995;11(2):219-22.
8. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375(6534):754-60.
9. Saura CA, Chen G, Malkani S, Choi S-Y, Takahashi RH, Zhang D, et al. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25(29):6755-64.
10. Saura CA, Choi S-Y, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42(1):23-36.
11. Adessi C, Frossard MJ, Boissard C, Fraga S, Bieler S, Ruckle T, et al. Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer’s Disease. J Biol Chem. 2003;278(16):13905-11.
12. Lee DC, Rizer J, Hunt JB, Selenica ML, Gordon MN, Morgan D. Review: experimental manipulations of microglia in mouse models of Alzheimer’s pathology: Activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol. 2013;39(1):69-85.
13. Lee YJ, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV. Molecular Structure of Amyloid Fibrils Controls the Relationship between Fibrillar Size and Toxicity. PLoS ONe. 2011;6(5):e20244.
14. imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D’Onofrio G, Logroscino G, et al. Therapeutic intervention for Alzheimer’s disease with γ-secretase inhibitors: still a viable option? expert Opin investig Drugs. 2011;20(3):325-41.
15. Chakroborty S, Stutzmann GE. Calcium channelopathies and Alzheimer’s disease: insight into therapeutic success and failures. eur J Pharmacol. 2014;739:83-95.
16. Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. expert Opin Pharmacother. 2014;15(13):1797-810.
17. Lanctot KL, Rajaram RD, Herrmann N. Therapy for Alzheimer’s Disease: How effective are Current Treatments? Ther Adv Neurol Disord. 2009;2(3):163-80.
18. Chen J, Armstrong AH, Koehler AN, Hecht MH. Small molecule microarrays enable the discovery of compounds that bind the Alzheimer’s Aβ peptide and reduce its cytotoxicity. J Am Chem Soc. 2010;132(47):17015-22.
19. Zhang C, Liu Y, Gilthorpe J, van der Maarel JRC. MRP14 (S100A9) protein interacts with Alzheimer beta-amyloid peptide and induces its fibrillization. PLoS ONe. 2012;7(3):e32953.
20. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson Ne, Smith i, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837-42.
21. irvine GB, el-Agnaf OM, Shankar GM, Walsh DM. Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases. Mol Med. 2008;14(7-8):451-64.
22. Lee H, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer’s disease: pathogen or protector? Trends Mol Med. 2005;11(4):164-9.
23. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286(39):34457-67.
24. Rapoport M, Dawson HN, Binder LI, vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99(9):6364-9.
25. Wegmann S, Jung YJ, Chinnathambi S, Mandelkow e-M, Mandelkow e, Muller DJ. Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem. 2010;285(35):27302-13.
26. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris eH, Glickman JF, Strickland S. Alzheimer’s disease peptide betaamyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A. 2010;107(50):21812-7.
27. Neurodegeneration: exploring Commonalities Across Diseases: Workshop Summary. National Academies Press [internet]. [cited 2013 Oct 10]. Available from: http://www.nap.edu/catalog.php?record_id=18341
28. vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, et al. Tau Reduction Prevents Aβ-induced Defects in Axonal Transport. Science. 2010;330(6001):198.
29. O’Connor T, Sadleir KR, Maus E, velliquette RA, Zhao J, Cole SL, et al. Phosphorylation of the translation initiation factor eiF2alpha increases BACe1 levels and promotes amyloidogenesis. Neuron. 2008;60(6):988-1009.
30. ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387-97.
31. Zhang Y, Thompson R, Zhang H, Xu H. APP processing in Alzheimer’s disease. Mol Brain. 2011;4:3.
32. Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, Patel AJ. Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Brain Res Mol Brain Res. 1997;47(1-2):147-56.
33. Kang J, Muller-Hill B. Differential splicing of Alzheimer’s disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain. Biochem Biophys Res Commun. 1990;166(3):1192-200.
34. Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, Calatayud MT, Blazquez Menes B. APP processing and the APP-KPi domain involvement in the amyloid cascade. Neurodegener Dis. 2005;2(6):277-83.
35. Bordji K, Becerril-Ortega J, Nicole O, Buisson A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-s production. J Neurosci. 2010;30(47):15927-42.
36. von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, van der Ploeg LH, et al. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol Aging. 1997;18(6):661-9.
37. Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci. 2000;20(21):7951-63.
38. Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, et al. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. eMBO J. 2004;23(20):4106-15.
39. Dulin F, Leveille F, Ortega JB, Mornon J-P, Buisson A, Callebaut I, et al. p3 peptide, a truncated form of Aβ devoid of synaptotoxic effect, does not assemble into soluble oligomers. FeBS Letters. 2008;582(13):1865-70.
40. Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, iwatsubo T, et al. Alzheimer’s A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat Med. 1997;3(9):1021-3.
41. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13(2):159-70.
42. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins v, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebocontrolled phase i trial. Lancet. 2008;372(9634):216-23.
43. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of Aβ 43. Nat Neurosci. 2011;14(8):1023-32.
44. Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, et al. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer’s disease. Nat Neurosci. 2000;3(5):460-4.
45. Ho A, Sudhof TC. Binding of F-spondin to amyloid-β precursor protein: A candidate amyloid-β precursor protein ligand that modulates amyloid-β precursor protein cleavage. Proc Natl Acad Sci U S A. 2004;101(8):2548-53.
46. Lourenço F, Galvan V, Fombonne J, Corset V, Llambi F, Müller U, et al. Netrin-1 interacts with amyloid precursor protein and regulates amyloid-β production. Cell Death Differ. 2009;16(5):655-63.
47. Yamazaki T, Koo EH, Selkoe DJ. Cell surface amyloid betaprotein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. J Neurosci. 1997;17(3):1004-10.
48. Wang Y, Ha Y. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein e2 domain. Mol Cell. 2004;15(3):343-53.
49. Soba P, eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, et al. Homo- and heterodimerization of APP family members promotes intercellular adhesion. eMBO J. 2005;24(20):3624-34.
50. Levites Y, Amit T, Mandel S, Youdim MBH. Neuroprotection and neurorescue against Aβtoxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)- epigallocatechin-3-gallate. FASeB J [internet]. 2003 Mar [cited 2016 Jan 21]. Available from: http://www.fasebj.org/content/early/2003/05/02/fj.02-0881fje.
51. Fernandez JW, Rezai-Zadeh K, Obregon D, Tan J. eGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. FeBS Lett. 2010;584(19):4259-67.
52. vassar R. The beta-secretase, BACe: a prime drug target for Alzheimer’s disease. J Mol Neurosci. 2001;17(2):157-70.
53. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACe1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25(50):11693-709.
54. Zetterberg H, Andreasson U, Hansson O, et al. elevated cerebrospinal fluid bace1 activity in incipient alzheimer disease. Arch Neurol. 2008;65(8):1102-7.
55. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo e, Colombatto S, et al. The up-regulation of BACe1 mediated by hypoxia and ischemic injury: role of oxidative stress and HiF1alpha. J Neurochem. 2009;108(4):1045-56.
56. Omar A, Jovanovic K, Da Costa Dias B, Gonsalves D, Moodley K, Caveney R, et al. Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor. expert Opin Ther Pat. 2011;21(1):35-53.
57. Mbazima V, DA Costa Dias B, Omar A, Jovanovic K, Weiss SFT. interactions between PrP(c) and other ligands with the 37-kDa/67-kDa laminin receptor. Front Biosci. 2010;15:1150-63.
58. Wolfe MS. inhibition and modulation of gamma-secretase for Alzheimer’s disease. Neurotherapeutics. 2008;5(3):391-8.
59. Li H, Wolfe MS, Selkoe DJ. Toward structural elucidation of the gamma-secretase complex. Structure. 2009;17(3):326-34.
60. Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2010;12(1):1-12.
61. Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci. 2008 May;65(9):1311-34.
62. Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda). 2008;23:194-204.
63. Zhong W, Jiang MM, Weinmaster G, Jan LY, Jan YN. Differential expression of mammalian Numb, Numblike and Notch1 suggests distinct roles during mouse cortical neurogenesis. Development. 1997;124(10):1887-97.
64. Marlow L, Canet RM, Haugabook SJ, Hardy JA, Lahiri DK, Sambamurti K. APH1, PeN2, and Nicastrin increase Abeta levels and gamma-secretase activity. Biochem Biophys Res Commun. 2003;305(3):502-9.
65. Li R, Lindholm K, Yang L-B, Yue X, Citron M, Yan R, et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci U S A. 2004;101(10):3632-7.
66. Holsinger RMD, McLean CA, Collins SJ, Masters CL, Evin G. increased beta-Secretase activity in cerebrospinal fluid of Alzheimer’s disease subjects. Ann Neurol. 2004;55(6):898-9.
67. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, irizarry MC. β-Secretase Activity increases with Aging in Human, Monkey, and Mouse Brain. Am J Pathol. 2004;164(2):719-25.
68. Devi L, Ohno M. A combination Alzheimer’s therapy targeting BACe1 and neprilysin in 5XFAD transgenic mice. Molecular Brain. 2015;8(1):19.
69. Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M. Familial Alzheimer’s disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. J Neurochem. 2005;94(5):1189-201.
70. Palmer AM. Neuroprotective therapeutics for Alzheimer’s disease: progress and prospects. Trends Pharmacol Sci. 2011;32(3):141-7.
71. Bettens K, Sleegers K, van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet. 2010;19(R1):R4-11.
72. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer’s disease locus on chromosome 1. Science. 1995;269(5226):970-3.
73. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science. 1995;269(5226):973-7.
74. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci U S A. 1997;94(6):2095-7.
75. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 1997;20(4):154-9.
76. Bettens K, Brouwers N, van Miegroet H, Gil A, engelborghs S, De Deyn PP, et al. Follow-up study of susceptibility loci for Alzheimer’s disease and onset age identified by genomewide association. J Alzheimers Dis. 2010;19(4):1169-75.
77. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774.
78. Motter R, vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson- Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol. 1995;38(4):643-8.
79. Dias BDC, Jovanovic K, Gonsalves D, Weiss SFT. Structural and mechanistic commonalities of amyloid-β and the prion protein. Prion. 2011;5(3):126-37.
80. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A. 2010;107(50):21812-7.
81. Svedružić ZM, Popović K, Smoljan i, Sendula-Jengić v. Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer’s disease. PLoS ONe. 2012;7(3):e32293.
82. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-66.
83. Rowe CC, ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian imaging, Biomarkers and Lifestyle (AiBL) study of aging. Neurobiol Aging. 2010;31(8):1275-83.
84. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119.
85. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PiB and MRi in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009;132(5):1355-65.
86. Dominantly inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in individuals at Risk for or With a Type of early Onset Alzheimer’s Disease Caused by a Genetic Mutation (Full Text view). ClinicalTrials.gov [internet]. [cited 2015 Jun 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01760005?term=sola nezumab&rank=4
87. Cummings BJ, Pike CJ, Shankle R, Cotman CW. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer’s disease. Neurobiol Aging. 1996;17(6):921-33.
88. Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol. 1994;10:373-403.
89. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. exp Neurol. 1999;158(2):328-37.
90. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol. 1999;46(6):860-6.
91. Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, et al. AL Amyloid imaging and Therapy with a Monoclonal Antibody to a Cryptic epitope on Amyloid Fibrils. PLoS ONe. 2012;7(12):e52686.
92. vandenberghe R, Adamczuk K, Dupont P, Laere KV, Chetelat G. Amyloid PeT in clinical practice: its place in the multidimensional space of Alzheimer’s disease. Neuroimage Clin. 2013;2:497-511.
93. vandenberghe R, Adamczuk K, van Laere K. The interest of amyloid PeT imaging in the diagnosis of Alzheimer’s disease. [Miscellaneous Article]. Curr Opin Neurol. 2013;26(6):646-55.
94. Leopoldo M, Contino M, Berardi F, Perrone R, Colabufo NA. PeT Radiotracers for imaging P-glycoprotein: The Challenge for early Diagnosis in AD. ChemMedChem. 2014;9(1):38-42.
95. Sepúlveda FJ, Fierro H, Fernandez E, Castillo C, Peoples RW, Opazo C, et al. Nature of the neurotoxic membrane actions of amyloid-β on hippocampal neurons in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):472-81.
96. Relini A, Marano N, Gliozzi A. Probing the interplay between amyloidogenic proteins and membranes using lipid monolayers and bilayers. Adv Colloid interface Sci. 2014;207:81-92.
97. Qiang W, Akinlolu RD, Nam M, Shu N. Structural evolution and Membrane interaction of the 40-Residue β Amyloid Peptides: Differences in the initial Proximity between Peptides and the Membrane Bilayer Studied by Solid-State Nuclear Magnetic Resonance Spectroscopy. Biochem. 2014;53(48):7503-14.
98. Head BP, Patel HH, insel PA. interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function. Biochim Biophys Acta. 2014;1838(2):532-45.
99. Dies H, Toppozini L, Rheinstadter MC. The interaction between Amyloid-β Peptides and Anionic Lipid Membranes Containing Cholesterol and Melatonin. PLoS One 2014;9(6): e99124.
100. Relini A, Marano N, Gliozzi A. Misfolding of Amyloidogenic Proteins and Their interactions with Membranes. Biomolecules. 2013;4(1):20-55.
101. Li H, Ye S, Wei F, Ma S, Luo Y. in Situ Molecular-Level insights into the interfacial Structure Changes of Membrane- Associated Prion Protein Fragment [118-135] investigated by Sum Frequency Generation vibrational Spectroscopy. LANGMUiR. 2012;28(49):16979-88.
102. Barrett PJ, Song Y, van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science. 2012;336(6085):1168-71.
103. Figueroa H, Peddi D, Osborne JM, Wilson BM, Pesaru RR, Kurva B, et al. Modeling the interface between islet amyloid polypeptide and insulin-based aggregation inhibitors: correlation to aggregation kinetics and membrane damage. J Chem inf Model. 2012;52(5):1298-307.
104. Björkhem I, Meaney S. Brain Cholesterol: Long Secret Life Behind a Barrier. Arterioscler Thromb vasc Biol. 2004;24(5):806-15.
105. Orth M, Bellosta S. Cholesterol: its Regulation and Role in Central Nervous System Disorders. Cholesterol. 2012;2012:292598.
106. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12(2):105-12.
107. Chen X, Hui L, Soliman ML, Geiger JD. Altered Cholesterol intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD. J Parkinsons Dis Alzheimers Dis. 2014;1(1):8.
108. Morris JK, Honea RA, vidoni ED, Swerdlow RH, Burns JM. is Alzheimer’s Disease a Systemic Disease? Biochim Biophys Acta. 2014;1842(9):1340-9.
109. Daneschvar HL, Aronson MD, Smetana GW. Do statins prevent Alzheimer’s disease? A narrative review. eur J intern Med. 2015;26(9):666-9.
110. Shobab LA, Hsiung G-YR, Feldman HH. Cholesterol in Alzheimer’s disease. Lancet Neurol. 2005;4(12):841-52.
111. Liu Q, Zerbinatti CV, Zhang J, Hoe H-S, Wang B, Cole SL, et al. Amyloid Precursor Protein Regulates Brain Apolipoprotein e and Cholesterol Metabolism through Lipoprotein Receptor LRP1. Neuron. 2007;56(1):66-78.
112. Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254-64.
113. Di Scala C, Troadec J-D, Lelievre C, Garmy N, Fantini J, Chahinian H. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide. J Neurochem. 2014;128(1):186-95.
114. Di Scala C, Chahinian H, Yahi N, Garmy N, Fantini J. interaction of Alzheimer’s β-Amyloid Peptides with Cholesterol: Mechanistic insights into Amyloid Pore Formation. Biochem. 2014;53(28):4489-502.
115. Fantini J, Di Scala C, Yahi N, Troadec J-D, Sadelli K, Chahinian H, et al. Bexarotene Blocks Calcium-Permeable ion Channels Formed by Neurotoxic Alzheimer’s β-Amyloid Peptides. ACS Chem Neurosci. 2014;5(3):216-24.
116. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein e genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(20):9649-53.
117. Cedazo-Mínguez A. Apolipoprotein e and Alzheimer’s disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007;11(6):1227-38.
118. Barberger-Gateau P, Samieri C, Féart C, Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer’s disease: interaction with apolipoprotein e genotype. Curr Alzheimer Res. 2011;8(5):479-91.
119. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-vance M, et al. Binding of human apolipoprotein e to synthetic amyloid beta peptide: isoform- specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(17):8098-102.
120. Strittmatter WJ, Saunders AM, Schmechel D, Pericakvance M, enghild J, Salvesen GS, et al. Apolipoprotein e: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977-81.
121. Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991;88(17):7552-6.
122. Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein e in the development and progression of Alzheimer’s disease. J Lipid Res. 2005;46(5):949-68.
123. vega G, Weiner MF, Lipton AM, et al. Reduction in levels of 24s-hydroxycholesterol by statin treatment in patients with alzheimer disease. Arch Neurol. 2003;60(4):510-5.
124. Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000;41(2):195-8.
125. Theendakara V, Peters-Libeu CA, Spilman P, Poksay KS, Bredesen DE, Rao RV. Direct Transcriptional effects of Apolipoprotein e. J Neurosci. 2016;36(3):685-700.
126. Ho A, Liu X, Südhof TC. Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer’s disease. J Neurosci. 2008;28(53):14392-400.
127. Sullivan SE, Dillon GM, Sullivan JM, Ho A. Mint Proteins Are Required for Synaptic Activity-dependent Amyloid Precursor Protein (APP) Trafficking and Amyloid β Generation. J Biol Chem. 2014;289(22):15374-83.
128. Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang Y. Trafficking regulation of proteins in Alzheimer’s disease. Mol Neurodegener. 2014;9(1):6.
129. Saluja I, Paulson H, Gupta A, Turner RS. X11α haploinsufficiency enhances Aβ amyloid deposition in Alzheimer’s disease transgenic mice. Neurobiol Dis. 2009;36(1):162-8.
130. Borg J-P, Yang Y, Taddéo-Borg MD, Margolis B, Turner RS. The X11α Protein Slows Cellular Amyloid Precursor Protein Processing and Reduces Aβ40 and Aβ42 Secretion. J Biol Chem. 1998;273(24):14761-6.
131. Sastre M, Turner RS, Levy E. X11 interaction with β-Amyloid Precursor Protein Modulates its Cellular Stabilization and Reduces Amyloid β-Protein Secretion. J Biol Chem. 1998;273(35):22351-7.
132. Chaufty J, Sullivan SE, Ho A. intracellular APP Sorting and Aβ Secretion are Regulated by Src-mediated Phosphorylation of Mint2. J Neurosci. 2012;32(28):9613-25.
133. Butz S, Okamoto M, Sudhof TC. A Tripartite Protein Complex with the Potential to Couple Synaptic vesicle exocytosis to Cell Adhesion in Brain. Cell. 1998;94(6):773-82.
134. Zhang Z, Lee C-H, Mandiyan V, Borg J-P, Margolis B, Schlessinger J, et al. Sequence-specific recognition of the internalization motif of the Alzheimer’s amyloid precursor protein by the X11 PTB domain. eMBO J. 1997;16(20):6141-50.
135. Lau KF, McLoughlin DM, Standen C, Miller CC. X11 alpha and x11 beta interact with presenilin-1 via their PDZ domains. Mol Cell Neurosci. 2000;16(5):557-65.
136. Ho CS, Marinescu V, Steinhilb ML, Gaut JR, Turner RS, Stuenkel EL. Synergistic effects of Munc18a and X11 proteins on amyloid precursor protein metabolism. J Biol Chem. 2002;277(30):27021-8.
137. Wang X, Huang T, Bu G, Xu H. Dysregulation of protein trafficking in neurodegeneration. Mol Neurodegener. 2014;9:31.
138. Mocchetti I. exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci. 2005;62(19-20):2283-94.
139. Grimm MOW, Zinser EG, Grösgen S, Hundsdörfer B, Rothhaar TL, Burg vK, et al. Amyloid precursor protein (APP) mediated regulation of ganglioside homeostasis linking Alzheimer’s disease pathology with ganglioside metabolism. PLoS One. 2012;7(3):e34095.
140. Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosović C, Lauc G. Human brain gangliosides in development, aging and disease. int J Dev Biol. 1991;35(3):289-95.
141. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Månsson J-e, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 2005;92(1):171-82.
142. Barrier L, ingrand S, Damjanac M, Rioux Bilan A, Hugon J, Page G. Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer’s disease. Neurobiol Aging. 2007;28(12):1863-72.
143. Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci: CMLS. 2007;64(17):2270-84.
144. Haass C, Koo EH, Teplow DB, Selkoe DJ. Polarized secretion of beta-amyloid precursor protein and amyloid betapeptide in MDCK cells. Proc Natl Acad Sci U S A. 1994;91(4):1564-8.
145. Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee J-M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A. 2009;106(48):20324-9.
146. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, ida N, Allsop D, et al. Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med. 1997;3(9):1016-20.
147. Grimm HS, Beher D, Lichtenthaler SF, Shearman MS, Beyreuther K, Hartmann T. gamma-Secretase cleavage site specificity differs for intracellular and secretory amyloid beta. J Biol Chem. 2003;278(15):13077-85.
148. Oikawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, et al. Gangliosides determine the amyloid pathology of Alzheimerʼs disease. Neuroreport. 2009;20(12);1043-6.
149. Bernardo A, Harrison Fe, McCord M, Zhao J, Bruchey A, Davies SS, et al. elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol Aging. 2009;30(11):1777-91.
150. Chatr-aryamontri A, Breitkreutz B-J, Heinicke S, Boucher L, Winter A, Stark C, et al. The BioGRiD interaction database: 2013 update. Nucleic Acids Res. 2013;41(D1):D816-23.
151. Wu G, Lu Z-H, Wang J, Wang Y, Xie X, Meyenhofer MF, et al. enhanced Susceptibility to Kainate-induced Seizures, Neuronal Apoptosis, and Death in Mice Lacking Gangliotetraose Gangliosides: Protection with LiGA 20, a Membrane-Permeant Analog of GM1. J Neurosci. 2005;25(47):11014-22.
152. vignaud H, Bobo C, Lascu I, Sorgjerd KM, Zako T, Maeda M, et al. A Structure-Toxicity Study of As42 Reveals a New Anti-Parallel Aggregation Pathway. PLoS One. 2013;8(11):e80262.
153. Qiang W, Yau W-M, Luo Y, Mattson MP, Tycko R. Antiparallel β-sheet architecture in iowa-mutant β-amyloid fibrils. Proc Natl Acad Sci U S A. 2012;109(12):4443-8.
154. Yau J, Sharpe S. Structures of amyloid fibrils formed by the prion protein derived peptides PrP(244-249) and PrP(245- 250). J Struct Biol. 2012;180(2):290-302.
155. eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell. 2012;148(6):1188-203.
156. Qiang W, Yau W-M, Luo Y, Mattson MP, Tycko R. Antiparallel β-sheet architecture in iowa-mutant β-amyloid fibrils. Proc Natl Acad Sci U S A. 2012;109(12):4443-8.
157. Colletier J-P, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, et al. Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A. 2011;108(41):16938-43.
158. Rosenman DJ, Connors C, Chen W, Wang C, Garcia AE. Aβ Monomers Transiently Sample Oligomer and Fibril-like Configurations: ensemble Characterization Using a Combined MD/NMR Approach. J Mol Biol. 2013;425(18):3338-59.
159. Scheidt HA, Morgado i, Rothemund S, Huster D. Dynamics of Amyloid β Fibrils Revealed by Solid-state NMR. J Biol Chem. 2012;287(3):2017-21.
160. Scheidt HA, Morgado I, Rothemund S, Huster D, Fandrich M. Solid-State NMR Spectroscopic investigation of Aβ Protofibrils: implication of a β-Sheet Remodeling upon Maturation into Terminal Amyloid Fibrils. Angew Chem int ed. 2011;50(12):2837-40.
161. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, et al. Structural conversion of neurotoxic amyloid-β(1-42) oligomers to fibrils. Nat Struct Mol Biol. 2010;17(5):561-7.
162. Gu L, Liu C, Guo Z. Structural insights into Aβ42 Oligomers Using Site-directed Spin Labeling. J Biol Chem. 2013;288(26):18673-83.
163. Debelouchina GT, Bayro MJ, Fitzpatrick AW, Ladizhansky v, Colvin MT, Caporini MA, et al. Higher Order Amyloid Fibril Structure by MAS NMR and DNP Spectroscopy. J Am Chem Soc. 2013;135(51):19237-47.
164. Fitzpatrick AWP, Debelouchina GT, Bayro MJ, Clare DK, Caporini MA, Bajaj vS, et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc Natl Acad Sci U S A. 2013;110(14):5468-73.
165. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A. 2009;106(35):14745-50.
166. Glabe CG. Structural Classification of Toxic Amyloid Oligomers. J Biol Chem. 2008;283(44):29639-43.
167. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, evangelisti e, et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010;6(2):140-7.
168. Nelson R, Sawaya M, Balbirnie M, Madsen A, Riekel C, Grothe R, et al. Structure of the cross-beta spine of amyloidlike fibrils. Nature. 2005;435(7043):773-8.
169. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447(7143):453-7.
170. Zheng X, Wu C, Ponder JW, Marshall GR. Molecular Dynamics of β-Hairpin Models of epigenetic Recognition Motifs. J Am Chem Soc. 2012;134(38):15970-8.
171. Xu W, Su H, Zhang JZH, Mu Y. Molecular Dynamics Simulation Study on the Molecular Structures of the Amylin Fibril Models. J Phys Chem B. 2012;116(48):13991-9.
172. Lapidus LJ. Understanding protein aggregation from the view of monomer dynamics. Mol Biosyst. 2013;9(1):29-35.
173. Chakraborty S, Chatterjee B, Basu S. A mechanistic insight into the amyloidogenic structure of hiAPP peptide revealed from sequence analysis and molecular dynamics simulation. Biophys Chem. 2012;168-169:1-9.
174. Berhanu WM, Masunov AE. Alternative packing modes leading to amyloid polymorphism in five fragments studied with molecular dynamics. Biopolymers. 2012;98(2):131-44.
175. Agopian A, Guo Z. Structural origin of polymorphism for Alzheimer’s amyloid-β fibrils. Biochem J. 2012;447(1):43-50.
176. Tycko R. Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem. 2011;62:279-99.
177. Torok M, Milton S, Kayed R, Wu P, Mcintire T, Glabe CG, et al. Structural and dynamic features of Alzheimer’s Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem. 2002;277(43):40810-5.
178. Liu C, Zhao M, Jiang L, Cheng P-N, Park J, Sawaya MR, et al. Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. Proc Natl Acad Sci U S A. 2012;109(51):20913-8.
179. Salemme FR. Structural properties of protein beta-sheets. Prog Biophys Mol Biol. 1983;42(2-3):95-133.
180. Arispe N, Pollard HB, Rojas e. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci U S A. 1993;90(22):10573-7.
181. Pollard HB, Rojas E, Arispe N. A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes. Ann N Y Acad Sci. 1993;695:165-8.
182. Nelson O, Supnet C, Tolia A, Horre K, De Strooper B, Bezprozvanny i. Mutagenesis Mapping of the Presenilin 1 Calcium Leak Conductance Pore. J Biol Chem. 2011;286(25):22339-47.
183. Diaz JC, Linnehan J, Pollard H, Arispe N. Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer’s disease Abeta ion channel and cytotoxicity. Biol Res. 2006;39(3):447-60.
184. Hirakura Y, Lin M-C, Kagan BL. Alzheimer amyloid aβ1– 42 channels: effects of solvent, pH, and congo red. J Neurosci Res. 1999;57(4):458-66.
185. Lin MA, Kagan BL. electrophysiologic properties of channels induced by Abeta25-35 in planar lipid bilayers. Peptides. 2002;23(7):1215-28.
186. Sanderson KL, Butler L, ingram vM. Aggregates of a betaamyloid peptide are required to induce calcium currents in neuron-like human teratocarcinoma cells: relation to Alzheimer’s disease. Brain Res. 1997;744(1):7-14.
187. Schauerte JA, Wong PT, Wisser KC, Ding H, Steel DG, Gafni A. Simultaneous Single Molecule Fluorescence and Conductivity Studies Reveal Distinct Classes of Aβ Species on Lipid Bilayers. Biochem. 2010;49(14):3031-9.
188. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head e, et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem. 2009;284(7):4230-7.
189. Demuro A, Smith M, Parker i. Single-channel Ca2+ imaging implicates Aβ1-42 amyloid pores in Alzheimer’s disease pathology. J Cell Biol. 2011;195(3):515-24.
190. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, et al. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer’s Disease and Down syndrome. Proc Natl Acad Sci U S A. 2010;107(14):6538-43.
191. Hagenston AM, Fitzpatrick JS, Yeckel MF. MGluR-Mediated Calcium Waves that invade the Soma Regulate Firing in Layer v Medial Prefrontal Cortical Pyramidal Neurons. Cereb Cortex. 2008;18(2):407-23.
192. Stutzmann Ge, Smith I, Caccamo A, Oddo S, LaFerla FM, Parker I. enhanced Ryanodine Receptor Recruitment Contributes to Ca2+ Disruptions in Young, Adult, and Aged Alzheimer’s Disease Mice. J Neurosci. 2006;26(19):5180-9.
193. verkhratsky A. The endoplasmic reticulum and neuronal calcium signalling. Cell Calcium. 2002;32(5-6):393-404.
194. Fitzjohn SM, Collingridge GL. Calcium stores and synaptic plasticity. Cell Calcium. 2002;32(5-6):405-11.
195. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44(1):5-21.
196. Malenka RC, Nicoll RA. Long-term potentiation—a decade of progress? Science. 1999;285(5435):1870-4.
197. Mulkey RM, Malenka RC. Mechanisms underlying induction of homosynaptic long-term depression in area CA1 of the hippocampus. Neuron. 1992;9(5):967-75.
198. Demuro A, Parker I. Cytotoxicity of intracellular Aβ42 amyloid oligomers involves Ca2+ release from the eR by stimulated production of inositol trisphosphate. J Neurosci. 2013;33(9):3824-33.
199. Yamasaki-Mann M, Demuro A, Parker i. Cytosolic [Ca2+] regulation of insP3-evoked puffs. Biochem J. 2013;449(1):167-73.
200. Christensen RA, Shtifman A, Allen PD, Lopez JR, Querfurth HW. Calcium Dyshomeostasis in β-Amyloid and Taubearing Skeletal Myotubes. J Biol Chem. 2004;279(51):53524-32.
201. Alberdi E, Sánchez-Gómez MV, Cavaliere F, Pérez- Samartin A, Zugaza JL, Trullas R, et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium. 2010;47(3):264-72.
202. Tabas I, Ron D. integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13(3):184-90.
203. Shore GC, Papa FR, Oakes SA. Signaling Cell Death from the endoplasmic Reticulum Stress Response. Curr Opin Cell Biol. 2011;23(2):143-9.
204. Malhotra JD, Kaufman RJ. eR Stress and its Functional Link to Mitochondria: Role in Cell Survival and Death. Cold Spring Harb Perspect Biol. 2011;3(9):a004424.
205. Bravo R, vicencio JM, Parra V, Troncoso R, Munoz JP, Bui M, et al. increased eR–mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of eR stress. J Cell Sci. 2011;124(13):2143-52.
206. Lee M-T, Chen F-Y, Huang HW. energetics of Pore Formation induced by Membrane Active Peptides. Biochem. 2004;43(12):3590-9.
207. Huang HW, Chen F-Y, Lee M-T. Molecular mechanism of Peptide-induced pores in membranes. Phys Rev Lett. 2004;92(19):198304.
208. Sparr E, Engel MFM, Sakharov DV, Sprong M, Jacobs J, de Kruijff B, et al. islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FeBS Letters. 2004;577(1-2):117-20.
209. Pieri L, Madiona K, Bousset L, Melki R. Fibrillar α-Synuclein and Huntingtin exon 1 Assemblies Are Toxic to the Cells. Biophys J. 2012;102(12):2894-905.
210. Connelly L, Jang H, Teran Arce F, Ramachandran S, Kagan BL, Nussinov R, et al. effects of Point Substitutions on the Structure of Toxic Alzheimer’s β-Amyloid Channels: Atomic Force Microscopy and Molecular Dynamics Simulations. Biochem. 2012;51(14):3031-8.
211. Shafrir Y, Durell SR, Anishkin A, Guy HR. Beta-barrel models of soluble amyloid beta oligomers and annular protofibrils. Proteins. 2010;78(16):3458-72.
212. Jang H, Arce FT, Ramachandran S, Capone R, Lal R, Nussinov R. β-Barrel topology of Alzheimer’s β-amyloid ion channels. J Mol Biol. 2010;404(5):917-34.
213. Schenk D, Barbour R, Dunn W, Gordon G, et al. immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-7.
214. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9(4):448-52.
215. Lambracht-Washington D, Rosenberg RN. Advances in the Development of vaccines for Alzheimer’s Disease. Discov Med. 2013;15(84):319-26.
216. Farlow MR, Andreasen N, Riviere M-E, vostiar I, vitaliti A, Sovago J, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease. Alzheimers Res Ther. 2015;7(1):23.
217. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916-9.
218. Lemere CA. immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener. 2013;8:36.
219. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, et al. A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease. Alzheimer Dis Assoc Disord. 2010;24(2):198-203.
220. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease. N engl J Med. 2014;370(4):322-33.
221. Rafii MS, Aisen PS. Advances in Alzheimer’s Disease Drug Development. BMC Med. 2015;13:62.
222. Samadi H, Sultzer D. Solanezumab for Alzheimer’s disease. expert Opin Biol Ther. 2011;11(6):787-98.
223. Doody RS, Thomas RG, Farlow M, iwatsubo T, vellas B, Joffe S, et al. Phase 3 Trials of Solanezumab for Mild-to- Moderate Alzheimer’s Disease. N engl J Med. 2014;370(4):311-21.
224. Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. A Randomized, Double-Blind, Placebo- Controlled Phase 2 Study To evaluate The efficacy And Safety Of Crenezumab in Patients With Mild To Moderate Alzheimer’s Disease. Alzheimers Dement: J Alzheimers Assoc. 10(4):P275.
225. vassar R. BACe1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther. 2014;6:89.
226. Forman M, Kleijn H-J, Dockendorf M, Palcza J, Tseng J, Canales C, et al. The novel BACe inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-tomoderate Alzheimer’s disease. Alzheimers Dement: J Alzheimers Assoc. 9(4):P139.
227. Cooper DJL. Dietary Lipids in the Aetiology of Alzheimer’s Disease. Drugs Aging. 2012;20(6):399-418.
228. Dannenberger D, Nuernberg G, Renne U, Nuernberg K, Langhammer M, Huber K, et al. High-fat diets rich in ω-3 or ω-6 polyunsaturated fatty acids have distinct effects on lipid profiles and lipid peroxidation in mice selected for either high body weight or leanness. Nutrition. 2013;29(5):765-71.
229. Wassall SR, Stillwell W. Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. Biochim Biophys Acta. 2009;1788(1):24-32.
230. Soni SP, LoCascio DS, Liu Y, Williams JA, Bittman R, Stillwell W, et al. Docosahexaenoic Acid enhances Segregation of Lipids between Raft and Nonraft Domains: 2H-NMR Study. Biophys J. 2008;95(1):203-14.
231. PyMOL. pyMol.org [internet]. Available at http://pymol.org.